Unicycive Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on October 17, 2024

Rhea-AI Summary

Unicycive Therapeutics (Nasdaq: UNCY), a clinical-stage biotechnology company focused on kidney disease therapies, has announced its participation in the 2024 Maxim Healthcare Virtual Summit. The company's CEO, Shalabh Gupta, M.D., will engage in a fireside chat on October 17, 2024, at 10:00 a.m. ET.

Interested parties can access the live and archived webcast through the Unicycive website under the Investors section, specifically in the Events and Presentations area. The webcast archive will remain available for three months following the event.

This participation provides an opportunity for investors and stakeholders to gain insights into Unicycive's developments and strategies in the field of kidney disease treatments.

LOS ALTOS, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today announced that Shalabh Gupta, M.D., Chief Executive Officer will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit on Thursday, October 17, 2024 at 10:00 a.m. ET.

A link to the live and archived webcast may be accessed on the Unicycive website under the Investors section: Events and Presentations. An archive of the webcast will be available for three months.

About Unicycive Therapeutics

Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug candidate, oxylanthanum carbonate (OLC), is a novel investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. UNI-494 is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury. For more information, please visit Unicycive.com and follow us on LinkedIn, X, and YouTube.

Investor Contact:

ir@unicycive.com
(650) 543-5470

SOURCE: Unicycive Therapeutics, Inc.

FAQ

When is Unicycive Therapeutics (UNCY) participating in the 2024 Maxim Healthcare Virtual Summit?

Unicycive Therapeutics (UNCY) is participating in the 2024 Maxim Healthcare Virtual Summit on Thursday, October 17, 2024, at 10:00 a.m. ET.

Who will represent Unicycive Therapeutics (UNCY) at the 2024 Maxim Healthcare Virtual Summit?

Shalabh Gupta, M.D., the Chief Executive Officer of Unicycive Therapeutics, will represent the company in a fireside chat at the 2024 Maxim Healthcare Virtual Summit.

How can investors access the webcast of Unicycive Therapeutics' (UNCY) fireside chat?

Investors can access the live and archived webcast of Unicycive Therapeutics' fireside chat on the company's website under the Investors section, in the Events and Presentations area.

How long will the archived webcast of Unicycive Therapeutics' (UNCY) fireside chat be available?

The archived webcast of Unicycive Therapeutics' fireside chat will be available for three months following the event.

What is the main focus of Unicycive Therapeutics (UNCY) as a biotechnology company?

Unicycive Therapeutics (UNCY) is a clinical-stage biotechnology company focused on developing therapies for patients with kidney disease.